このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Mereo BioPharma Group 将来の成長

Future 基準チェック /26

Mereo BioPharma Groupの収益は年間20.4%で減少すると予測されていますが、年間収益は年間44.4%で増加すると予想されています。EPS は年間27.4%で増加すると予想されています。

主要情報

-18.1%

収益成長率

29.6%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	47.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	21 Jun 2024

今後の成長に関する最新情報

更新なし

Recent updates

Mereo activist investor Rubric asks board again to hold general meeting, nominate directors

Sep 14

Mereo BioPharma Group regains compliance with Nasdaq's listing rule

Jul 05

Mereo BioPharma: Activist Pressure In A Net-Net Biopharma

Jun 17

Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development

Dec 08

Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study

Apr 30

業績と収益の成長予測

NasdaqCM:MREO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	22	-65	-33	N/A	2
12/31/2025	16	-33	-27	N/A	5
12/31/2024	14	-16	-13	N/A	5
3/31/2024	10	-26	-21	-20	N/A
12/31/2023	10	-29	-22	-21	N/A
9/30/2023	9	-32	-33	-33	N/A
6/30/2023	9	-33	-43	-42	N/A
3/31/2023	N/A	-42	-46	-46	N/A
12/31/2022	N/A	-42	-47	-49	N/A
9/30/2022	N/A	-31	-42	-43	N/A
6/30/2022	N/A	-23	-40	-41	N/A
3/31/2022	24	-4	-25	-26	N/A
12/31/2021	49	17	-8	-7	N/A
9/30/2021	49	-10	-9	-8	N/A
6/30/2021	50	-37	-10	-10	N/A
3/31/2021	25	-131	-23	-25	N/A
12/31/2020	N/A	-224	-36	-39	N/A
9/30/2020	N/A	-198	-35	-37	N/A
6/30/2020	N/A	-177	-34	-36	N/A
3/31/2020	N/A	-111	-46	-47	N/A
12/31/2019	N/A	-46	-61	-61	N/A
9/30/2019	N/A	-41	-50	-50	N/A
6/30/2019	N/A	-40	-45	-45	N/A
3/31/2019	N/A	-41	-38	-38	N/A
12/31/2018	N/A	-41	-30	-29	N/A
9/30/2018	N/A	-42	-41	-39	N/A
6/30/2018	N/A	-44	-51	-48	N/A
3/31/2018	N/A	-50	-52	-48	N/A
12/31/2017	N/A	-52	N/A	-43	N/A
9/30/2017	N/A	-50	N/A	-41	N/A
6/30/2017	N/A	-47	N/A	-39	N/A
3/31/2017	N/A	-41	N/A	-37	N/A
12/31/2016	N/A	-35	N/A	-37	N/A
6/30/2016	N/A	-39	N/A	-25	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MREO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MREO今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: MREO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MREOの収益 ( 44.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: MREOの収益 ( 44.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MREOの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Mereo BioPharma Group 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

Mereo BioPharma Group plc has filed a Follow-on Equity Offering in the amount of $49.999887 million.

Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study

Mereo BioPharma Group plc, Annual General Meeting, May 23, 2024

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc. Announces Data from the Dose- Selection Phase 2/3 Orbit Study

Mereo BioPharma Group plc Presents Phase 2 Data from “ASTRAEUS” Trial of Its Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease at the 2023 American Thoracic Society International Conference

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?

Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?

Less than half of directors are independent

Less than half of directors are independent

Mereo BioPharma Receives Notification of Nasdaq Minimum Bid Price Deficiency

Mereo Biopharma Group plc Announces Board Changes

Rubric Capital Management LP Comments on Mereo BioPharma Group Plc Updated Operating Plan

Mereo BioPharma Group plc Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat

Rubric Capital boosts Mereo BioPharma board nominees slate to five

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

Rubric Capital Management LP Issues a Letter to the Shareholders of Mereo BioPharma Group plc

Rubric Capital Management LP Issues a Letter to the Shareholders of Mereo BioPharma Group plc

Mereo activist investor Rubric asks board again to hold general meeting, nominate directors

Mereo Biopharma Group plc Reports Clinical Update and Interim Biomarker Analysis Presented At Esmo 2022 from Activate Phase 1B/2 Open Label Study of Etigilimab (Anti-Tigit Antibody Mph-313) Plus Nivolumab (Anti-Pd-1 Antibody) in Solid Tumors

Rubric Capital Management LP Delivers a Letter to Mereo BioPharma Group

Mereo BioPharma Group plc Announces Board Changes

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mereo BioPharma Group regains compliance with Nasdaq's listing rule

Astrazeneca Reportedly Considering Take over Offer for Mereo

Mereo BioPharma: Activist Pressure In A Net-Net Biopharma

Rubric Capital Sends Letter to Mereo BioPharma

Mereo BioPharma Group plc to Present Data Update for the Phase 1B/2 Study (Activate) of Etigilimab and Nivolumab At 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan

Rubric Capital Discloses its Views on Mereo BioPharma

Mereo BioPharma Receives Notification of Nasdaq Minimum Bid Price Deficiency

Mereo BioPharma Group plc Announces Board Changes

Mereo BioPharma Group plc Announces Positive Top-Line Efficacy and Safety Data from “Astraeus” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Emphysema

Mereo BioPharma Group plc Announces Appointment of Anne Hyland to Board of Directors

The University of Alabama at Birmingham and Mereo BioPharma Group plc, Announces Positive Top-Line Results from “Costa” A Phase 1B/2 Trial of Alvelestat in Hospitalized Patients with Covid-19 Respiratory Disease

Mereo Biopharma Group plc to Present Biomarker Data from Phase 1B/2 Investigator-Sponsored Trial of Alvelestat in Bronchiolitis Obliterans Syndrome at the ASH Annual Meeting

Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development

Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)

Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study

Mereo BioPharma Group plc has completed a Follow-on Equity Offering in the amount of $100.05 million.

Mereo BioPharma Group plc, Annual General Meeting, Feb 01, 2021

Ultragenyx Pharmaceutical Inc. and Mereo Biopharma Group plc Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

Mereo Biopharma Provides Update with Respect to the Cancellation of Admission of Its Ordinary Shares to Trading on Aim

Mereo Biopharma Group plc Announces the Appointment of Suba Krishnan, M.D. as Senior Vice President of Clinical Development, Effective December 7, 2020

Mereo BioPharma Group Plans Cancellation of Admission of Its Ordinary Shares to Trading on AIM

Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)

Mereo BioPharma Group plc Announces Changes to Board of Directors

Mereo Biopharma Group plc Receives U.S. Food and Drug Administration Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta

Mereo BioPharma Group plc Announces Initiation of Placebo-Controlled Phase 1B/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘